Trojan, Lutz

[["dc.bibliographiccitation.firstpage","1293"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Radiology"],["dc.bibliographiccitation.lastpage","1307"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Rücker, Gerta"],["dc.contributor.author","Hosseini, Ali Seif Amir"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Kim, Hyun S."],["dc.contributor.author","Uhlig, Annemarie"],["dc.date.accessioned","2019-08-05T10:33:02Z"],["dc.date.available","2019-08-05T10:33:02Z"],["dc.date.issued","2018"],["dc.description.abstract","Purpose To compare partial nephrectomy (PN), radiofrequency ablation (RFA), cryoablation (CRA) and microwave ablation (MWA) regarding oncologic, perioperative and functional outcomes. Material and methods The MEDLINE, EMBASE and COCHRANE libraries were searched for studies comparing PN, RFA, CRA or MWA and reporting on any-cause or cancer-specific mortality, local recurrence, complications or renal function. Network meta-analyses were performed. Results Forty-seven studies with 24,077 patients were included. Patients receiving RFA, CRA or MWA were older and had more comorbidities compared with PN. All-cause mortality was higher for CRA and RFA compared with PN (incidence rate ratio IRR = 2.58, IRR = 2.58, p < 0.001, respectively). No significant differences in cancer-specific mortality were evident. Local recurrence was higher for CRA, RFA and MWA compared with PN (IRR = 4.13, IRR = 1.79, IRR = 2.52, p < 0.05 respectively). A decline in renal function was less pronounced after RFA versus PN, CRA and MWA (mean difference in GFR MD = 6.49; MD = 5.82; MD = 10.89, p < 0.05 respectively). Conclusion Higher overall survival and local control of PN compared with ablative therapies did not translate into significantly better cancer-specific mortality. Most studies carried a high risk of bias by selecting younger and healthier patients for PN, which may drive superior survival and local control. Physicians should be aware of the lack of high-quality evidence and the potential benefits of ablative techniques for certain patients, including a superior complication profile and renal function preservation. Key Points • Patients selected for ablation of small renal masses are older and have more comorbidities compared with those undergoing partial nephrectomy. • Partial nephrectomy yields lower all-cause mortality, which is probably biased by patient selection and does not translate into prolonged cancer-free survival. • The decline of renal function is smallest after radiofrequency ablation for small renal masses."],["dc.identifier.doi","10.1007/s00330-018-5660-3"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/62282"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","0938-7994"],["dc.relation.issn","1432-1084"],["dc.title","Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","564"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Vascular and Interventional Radiology"],["dc.bibliographiccitation.lastpage","571"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Kim, Hyun S."],["dc.date.accessioned","2020-12-10T15:20:09Z"],["dc.date.available","2020-12-10T15:20:09Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1016/j.jvir.2019.11.009"],["dc.identifier.issn","1051-0443"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72570"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Stereotactic Body Radiotherapy for Stage I Renal Cell Carcinoma: National Treatment Trends and Outcomes Compared to Partial Nephrectomy and Thermal Ablation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","924"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","European Urology Focus"],["dc.bibliographiccitation.lastpage","936"],["dc.bibliographiccitation.volume","4"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Seif Amir Hosseini, Ali"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Schmid, Marianne"],["dc.contributor.author","Uhlig, Johannes"],["dc.date.accessioned","2020-12-10T14:23:51Z"],["dc.date.available","2020-12-10T14:23:51Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/j.euf.2017.08.007"],["dc.identifier.issn","2405-4569"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72062"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Gender-specific Differences in Recurrence of Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e002949"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Journal for Immunotherapy of Cancer"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Klümper, Niklas"],["dc.contributor.author","Ralser, Damian J."],["dc.contributor.author","Zarbl, Romina"],["dc.contributor.author","Schlack, Katrin"],["dc.contributor.author","Schrader, Andres Jan"],["dc.contributor.author","Rehlinghaus, Marc"],["dc.contributor.author","Hoffmann, Michèle J."],["dc.contributor.author","Niegisch, Günter"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Dietrich, Dimo"],["dc.date.accessioned","2021-10-01T09:58:08Z"],["dc.date.available","2021-10-01T09:58:08Z"],["dc.date.issued","2021"],["dc.description.abstract","Background In metastatic clear cell renal cell carcinoma (ccRCC), different combination therapies, each including anti-PD-1 immune checkpoint blockade (ICB), are applied as first-line treatment. Robust predictive biomarkers for rational upfront therapy decisions are lacking, although they are urgently needed. Recently, we showed that CTLA4 promoter methylation predicts response to ICB in melanoma. Here, we aimed to investigate CTLA4 methylation in ccRCC and its utility to serve as a predictive biomarker for anti-PD-1 based ICB in metastatic ccRCC. Methods CTLA4 methylation was analyzed with regard to transcriptional gene activity (mRNA expression), intratumoral immune cell composition, and clinical course in two ccRCC cohorts obtained from The Cancer Genome Atlas (TCGA cohort, n=533) and the University Hospital Bonn (UHB Non-ICB Cohort, n=116). In addition, CTLA4 methylation as well as CD8 + T cell infiltrates and PD-L1 expression were evaluated in pre-treatment samples from a multicenter cohort (RCC-ICB Cohort, n=71). Patients included in the RCC-ICB Cohort were treated with either first line anti-PD-1 based combination therapy (n=25) or monotherapy post–tyrosine kinase inhibition in second line or later. Analyses were performed with regard to treatment response according to RECIST, progression-free survival (PFS), event-free survival (EFS), and overall survival (OS) following treatment initiation. Results CTLA4 promoter hypomethylation was significantly correlated with CTLA4 mRNA expression, lymphocyte infiltration, and poor OS in both primary ccRCC cohorts (TCGA: HR 0.30 (95% CI 0.18 to 0.49), p<0.001; UHB Non-ICB: HR 0.35 (95% CI 0.16 to 0.75), p=0.007). In contrast, CTLA4 promoter hypomethylation predicted response and, accordingly, favorable outcomes (PFS and OS) in patients with ICB-treated ccRCC, overcompensating the negative prognostic value of CTLA4 hypomethylation at initial diagnosis. Moreover, in multivariable Cox regression, CTLA4 promoter hypomethylation remained an independent predictor of improved outcome in ICB-treated ccRCC after co-adjustment of the International Metastatic Renal Cell Carcinoma Database Consortium score (HR 3.00 (95% CI 1.47 to 6.28), p=0.003). Conclusions Our study suggests CTLA4 methylation as a powerful predictive biomarker for immunotherapy response in metastatic RCC."],["dc.identifier.doi","10.1136/jitc-2021-002949"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/89993"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-469"],["dc.relation.eissn","2051-1426"],["dc.title","CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","JORS-D-20-00102R1"],["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Journal of Robotic Surgery"],["dc.bibliographiccitation.lastpage","9"],["dc.contributor.author","Leitsmann, Conrad"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Popeneciu, I. Valentin"],["dc.contributor.author","Boos, Margarete"],["dc.contributor.author","Ahyai, Sascha A."],["dc.contributor.author","Schmid, Marianne"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Friedrich, Martin"],["dc.date.accessioned","2021-06-01T10:49:20Z"],["dc.date.available","2021-06-01T10:49:20Z"],["dc.date.issued","2020"],["dc.description.abstract","To reduce noise pollution and consequently stress during robot-assisted laparoscopic radical prostatectomy (RALP) the aim of our study was to evaluate the silent operation theatre optimisation system (SOTOS) in its effectiveness. In the operating room (OR) the noise level is between 80 and 85 decibel (dB). Noise corresponds to a major stress factor for surgical teams and especially surgeons. The use of the da Vinci surgical system entails an additional aspect of noise in the OR. The SOTOS surgical team used wired or wireless headphone/microphone combinations to communicate. We measured sound pressure levels in two different locations in the OR and the heart rate of every surgical team member as an indicator of the stress level. We further captured subjective acceptance of SOTOS as well as perioperative data such as surgical time. We prospectively randomised 32 RALP patients into two study arms. Sixteen surgeries were performed using SOTOS and 16 without (con- trol). Overall, the mean sound pressure level in the SOTOS group was 3.6 dB lower compared to the control (p < 0.001). The highest sound pressure level measured was 96 dB in the control group. Mean heart rates were 81.3 beats/min for surgeons and 90.8 beats/min for circulating nurses. SOTOS had no statistically significant effect on mean heart rates of the operating team. Subjective acceptance of SOTO was high. Our prospective evaluation of SOTOS in RALP could show a significant noise reduction in the OR and a high acceptance by the surgical stuff."],["dc.identifier.doi","10.1007/s11701-020-01135-x"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86250"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1863-2491"],["dc.relation.issn","1863-2483"],["dc.title","The Silent Operation Theatre Optimisation System (SOTOS©) to reduce noise pollution during da Vinci robot-assisted laparoscopic radical prostatectomy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","45"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Future Oncology"],["dc.bibliographiccitation.lastpage","56"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Woike, Michael"],["dc.contributor.author","Leitsmann, Marianne"],["dc.contributor.author","Strauß, Arne"],["dc.date.accessioned","2021-04-14T08:31:26Z"],["dc.date.available","2021-04-14T08:31:26Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.2217/fon-2020-0900"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83595"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1744-8301"],["dc.relation.issn","1479-6694"],["dc.title","Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Der Urologe"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Baunacke, Martin"],["dc.contributor.author","Groeben, Christer"],["dc.contributor.author","Borkowetz, Angelika"],["dc.contributor.author","Volkmer, Björn"],["dc.contributor.author","Ahyai, Sascha A."],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Eisenmenger, Nicole"],["dc.contributor.author","Schneider, Andreas"],["dc.contributor.author","Thomas, Christian"],["dc.contributor.author","Leitsmann, Marianne"],["dc.date.accessioned","2022-04-01T10:01:12Z"],["dc.date.available","2022-04-01T10:01:12Z"],["dc.date.issued","2022"],["dc.description.abstract","Zusammenfassung Hintergrund Die operative Therapie des benignen Prostatatsyndroms (BPS) hat in den letzten Jahren an Diversität gewonnen. Ziel der Arbeit Ziel dieser Studie ist die Darstellung aktueller Therapietrends sowie der Versorgungssituation in Deutschland. Material und Methoden Auf Basis der Qualitätsberichte der Krankenhäuser wurden mithilfe der Onlineplattform reimbursement.INFO Diagnose- wie Eingriffszahlen erhoben. Für die benigne Prostatahyperplasie (BPH) wurden die ICD-Codes N40 und D29.1 ausgewertet. Die Prozeduren wurden mittels der OPS-Codes 5‑600.0, 5‑601, 5‑603, 5‑609.4 und 5‑609.8 inklusive Subcodierungen extrahiert. Es erfolgten eine deskriptive Darstellung, Trend- und Korrelationsanalysen. Ergebnisse Insgesamt wurden 2019 83.687 BPS-Operationen in 473 urologischen Fachabteilungen durchgeführt. Am häufigsten wurde die transurethrale Prostataresektion (TURP; 71,7 %) angewendet. Die Holmiumlaserenukleation (HoLEP; 9,5 %) bzw. die chirurgische Adenomektomie (5,6 %) waren das zweit- bzw. dritthäufigste Verfahren. Seltener wurden Thuliumlaserenukleation (ThuLEP; 3,1 %), Laservaporisation (2,9 %) und elektrische Vaporisation (2,8 %) durchgeführt. Alle weiteren Verfahren machten jeweils < 1 % aus. HoLEP, ThuLEP und elektrische Vaporisation erlebten seit 2006 eine stetige Zunahme der Eingriffszahlen (HoLEP: +42,42 %/Jahr; p  < 0,001, ThuLEP: +20,6 %/Jahr, p  = 0,99; elektrische Vaporisation: +43,42 %/Jahr, p  < 0,001), während die chirurgische Adenomektomie abnahm (−1,66 %/Jahr, p  < 0,001). Die Krankenhausverweildauer lag 2019 bei mittleren 5,1 ± 0,1 Tagen. Schlussfolgerung Die TURP bleibt das am häufigsten durchgeführte Operationsverfahren. Während, insbesondere in Zentren, die Lasertherapien zunehmen, geht die chirurgische Adenomektomie zurück."],["dc.identifier.doi","10.1007/s00120-022-01777-9"],["dc.identifier.pii","1777"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105621"],["dc.language.iso","de"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1433-0563"],["dc.relation.issn","0340-2592"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Die operative Therapie des benignen Prostatasyndroms in Deutschland"],["dc.title.alternative","Eine Darstellung der Versorgungssituation auf Basis der Qualitätsberichte von 2006 bis 2019"],["dc.title.translated","Contemporary surgical management of benign prostatic obstruction in Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","48"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Urology"],["dc.bibliographiccitation.lastpage","60"],["dc.bibliographiccitation.volume","200"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Seif Amir Hosseini, Ali"],["dc.contributor.author","Simon, Jörg"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Schmid, Marianne"],["dc.contributor.author","Uhlig, Johannes"],["dc.date.accessioned","2020-12-10T15:20:08Z"],["dc.date.available","2020-12-10T15:20:08Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/j.juro.2017.11.150"],["dc.identifier.eissn","1527-3792"],["dc.identifier.issn","0022-5347"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72566"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Gender Specific Differences in Disease-Free, Cancer Specific and Overall Survival after Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","277"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","CardioVascular and Interventional Radiology"],["dc.bibliographiccitation.lastpage","283"],["dc.bibliographiccitation.volume","41"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Hahn, Oliver"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Müller-Wille, René"],["dc.contributor.author","Uhlig, Johannes"],["dc.date.accessioned","2020-12-10T14:10:01Z"],["dc.date.available","2020-12-10T14:10:01Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1007/s00270-017-1816-9"],["dc.identifier.eissn","1432-086X"],["dc.identifier.issn","0174-1551"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70640"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Treatment for Localized T1a Clear Cell Renal Cell Carcinoma: Survival Benefit for Cryosurgery and Thermal Ablation Compared to Deferred Therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e16111"],["dc.bibliographiccitation.issue","15_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","e16111"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Kim, Hyun S."],["dc.date.accessioned","2020-12-10T18:41:37Z"],["dc.date.available","2020-12-10T18:41:37Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1200/JCO.2019.37.15_suppl.e16111"],["dc.identifier.eissn","1527-7755"],["dc.identifier.issn","0732-183X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77630"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Stereotactic radiotherapy for stage I renal cell carcinoma: Overall survival and treatment trends compared to thermal ablation and surgical resection."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]